Analysts’ Weekly Ratings Updates for Structure Therapeutics (GPCR)

Structure Therapeutics (NASDAQ: GPCR) recently received a number of ratings updates from brokerages and research firms:

• 12/19/2025 – Structure Therapeutics had its price target raised by analysts at HC Wainwright from $60.00 to $90.00. They now have a “buy” rating on the stock.
• 12/13/2025 – Structure Therapeutics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 12/12/2025 – Structure Therapeutics had its price target raised by analysts at Morgan Stanley from $120.00 to $125.00. They now have an “overweight” rating on the stock.
• 12/12/2025 – Structure Therapeutics had its “outperform” rating reaffirmed by analysts at Citigroup Inc..
• 12/12/2025 – Structure Therapeutics had its price target raised by analysts at Citizens Jmp from $87.00 to $120.00. They now have a “market outperform” rating on the stock.
• 12/11/2025 – Structure Therapeutics was given a new $125.00 price target on by analysts at Jefferies Financial Group Inc.. They now have a “buy” rating on the stock.
• 12/9/2025 – Structure Therapeutics had its price target raised by analysts at Citigroup Inc. from $60.00 to $100.00. They now have a “buy” rating on the stock.
• 12/8/2025 – Structure Therapeutics had its price target raised by analysts at Stifel Nicolaus from $50.00 to $90.00. They now have a “buy” rating on the stock.
• 12/8/2025 – Structure Therapeutics had its price target raised by analysts at Jefferies Financial Group Inc. from $79.00 to $125.00. They now have a “buy” rating on the stock.
• 12/2/2025 – Structure Therapeutics was given a new $50.00 price target on by analysts at Stifel Nicolaus.
• 11/28/2025 – Structure Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
• 11/24/2025 – Structure Therapeutics had its “market outperform” rating reaffirmed by analysts at Citigroup Inc..
• 10/28/2025 – Structure Therapeutics had its “overweight” rating reaffirmed by analysts at Piper Sandler.

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.